The NuRD Chromatin-Remodeling Enzyme CHD4 Promotes Embryonic Vascular Integrity by Transcriptionally Regulating Extracellular Matrix Proteolysis

English version České info

The extracellular matrix (ECM) supports vascular integrity during embryonic development. Proteolytic degradation of ECM components is required for angiogenesis, but excessive ECM proteolysis causes blood vessel fragility and hemorrhage. Little is understood about how ECM proteolysis is transcriptionally regulated during embryonic vascular development. We now show that the NuRD ATP-dependent chromatin-remodeling complex promotes vascular integrity by preventing excessive ECM proteolysis in vivo. Mice lacking endothelial CHD4—a catalytic subunit of NuRD complexes—died at midgestation from vascular rupture. ECM components surrounding rupture-prone vessels in Chd4 mutants were significantly downregulated prior to embryonic lethality. Using qPCR arrays, we found two critical mediators of ECM stability misregulated in mutant endothelial cells: the urokinase-type plasminogen activator receptor (uPAR or Plaur) was upregulated, and thrombospondin-1 (Thbs1) was downregulated. Chromatin immunoprecipitation assays showed that CHD4-containing NuRD complexes directly bound the promoters of these genes in endothelial cells. uPAR and THBS1 respectively promote and inhibit activation of the potent ECM protease plasmin, and we detected increased plasmin activity around rupture-prone vessels in Chd4 mutants. We rescued ECM components and vascular rupture in Chd4 mutants by genetically reducing urokinase (uPA or Plau), which cooperates with uPAR to activate plasmin. Our findings provide a novel mechanism by which a chromatin-remodeling enzyme regulates ECM stability to maintain vascular integrity during embryonic development.

Vyšlo v časopise: The NuRD Chromatin-Remodeling Enzyme CHD4 Promotes Embryonic Vascular Integrity by Transcriptionally Regulating Extracellular Matrix Proteolysis. PLoS Genet 9(12): e32767. doi:10.1371/journal.pgen.1004031
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004031

Souhrn

Zdroje

1. DavisGE, SengerDR (2005) Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97: 1093–1107.

2. MurakamiM, SimonsM (2009) Regulation of vascular integrity. J Mol Med 87: 571–582.

3. SakalihasanN, LimetR, DefaweOD (2005) Abdominal aortic aneurysm. Lancet 365: 1577–1589.

4. RuigrokYM, RinkelGJ, WijmengaC (2005) Genetics of intracranial aneurysms. Lancet Neurol 4: 179–189.

5. PoschlE, Schlotzer-SchrehardtU, BrachvogelB, SaitoK, NinomiyaY, et al. (2004) Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 131: 1619–1628.

6. TangN, MackF, HaaseVH, SimonMC, JohnsonRS (2006) pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26: 2519–2530.

7. PhoonCK, AristizabalO, TurnbullDH (2000) 40 MHz Doppler characterization of umbilical and dorsal aortic blood flow in the early mouse embryo. Ultrasound Med Biol 26: 1275–1283.

8. ChangS, YoungBD, LiS, QiX, RichardsonJA, et al. (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321–334.

9. OhJ, TakahashiR, KondoS, MizoguchiA, AdachiE, et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789–800.

10. van HinsberghVW, KoolwijkP (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78: 203–212.

11. ChangCP, BruneauB (2011) Epigenetics and Cardiovascular Development. Annu Rev Physiol 74: 41–68.

12. OhtaniK, DimmelerS (2011) Epigenetic regulation of cardiovascular differentiation. Cardiovasc Res 90: 404–412.

13. CurtisCD, DavisRB, IngramKG, GriffinCT (2012) Chromatin-remodeling complex specificity and embryonic vascular development. Cell Mol Life Sci 69: 3921–3931.

14. van WeerdJH, Koshiba-TakeuchiK, KwonC, TakeuchiJK (2011) Epigenetic factors and cardiac development. Cardiovasc Res 91: 203–211.

15. TongJK, HassigCA, SchnitzlerGR, KingstonRE, SchreiberSL (1998) Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395: 917–921.

16. WadePA, JonesPL, VermaakD, WolffeAP (1998) A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase. Curr Biol 8: 843–846.

17. XueY, WongJ, MorenoGT, YoungMK, CoteJ, et al. (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2: 851–861.

18. ZhangY, LeRoyG, SeeligHP, LaneWS, ReinbergD (1998) The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95: 279–289.

19. LaiAY, WadePA (2011) Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer 11: 588–596.

20. WilliamsCJ, NaitoT, ArcoPG, SeavittJR, CashmanSM, et al. (2004) The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. Immunity 20: 719–733.

21. MiccioA, WangY, HongW, GregoryGD, WangH, et al. (2010) NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. Embo J 29: 442–456.

22. HungH, KohnkenR, SvarenJ (2012) The nucleosome remodeling and deacetylase chromatin remodeling (NuRD) complex is required for peripheral nerve myelination. J Neurosci 32: 1517–1527.

23. CurtisCD, GriffinCT (2012) The chromatin-remodeling enzymes BRG1 and CHD4 antagonistically regulate vascular Wnt signaling. Mol Cell Biol 32: 1312–1320.

24. CoultasL, ChawengsaksophakK, RossantJ (2005) Endothelial cells and VEGF in vascular development. Nature 438: 937–945.

25. StankunasK, HangCT, TsunZY, ChenH, LeeNV, et al. (2008) Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev Cell 14: 298–311.

26. MeyerD, BirchmeierC (1995) Multiple essential functions of neuregulin in development. Nature 378: 386–390.

27. GassmannM, CasagrandaF, OrioliD, SimonH, LaiC, et al. (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378: 390–394.

28. LeeKF, SimonH, ChenH, BatesB, HungMC, et al. (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394–398.

29. SuriC, JonesPF, PatanS, BartunkovaS, MaisonpierrePC, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180.

30. CamenischTD, SpicerAP, Brehm-GibsonT, BiesterfeldtJ, AugustineML, et al. (2000) Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 106: 349–360.

31. CattelinoA, LiebnerS, GalliniR, ZanettiA, BalconiG, et al. (2003) The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol 162: 1111–1122.

32. GeorgeEL, Georges-LabouesseEN, Patel-KingRS, RayburnH, HynesRO (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119: 1079–1091.

33. OrrAW, LeeMY, LemmonJA, YurdagulAJr, GomezMF, et al. (2009) Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 29: 225–231.

34. ArmulikA, AbramssonA, BetsholtzC (2005) Endothelial/pericyte interactions. Circ Res 97: 512–523.

35. HolycrossBJ, BlankRS, ThompsonMM, PeachMJ, OwensGK (1992) Platelet-derived growth factor-BB-induced suppression of smooth muscle cell differentiation. Circ Res 71: 1525–1532.

36. CorjayMH, ThompsonMM, LynchKR, OwensGK (1989) Differential effect of platelet-derived growth factor- versus serum-induced growth on smooth muscle alpha-actin and nonmuscle beta-actin mRNA expression in cultured rat aortic smooth muscle cells. J Biol Chem 264: 10501–10506.

37. BlasiF, SideniusN (2010) The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584: 1923–1930.

38. WangSJ, GreerP, AuerbachR (1996) Isolation and propagation of yolk-sac-derived endothelial cells from a hypervascular transgenic mouse expressing a gain-of-function fps/fes proto-oncogene. In Vitro Cell Dev Biol Anim 32: 292–299.

39. GhoshS, JohnsonJJ, SenR, MukhopadhyayS, LiuY, et al. (2006) Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem 281: 13021–13029.

40. SmithHW, MarshallCJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23–36.

41. ReynoldsN, Salmon-DivonM, DvingeH, Hynes-AllenA, BalasooriyaG, et al. (2012) NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. Embo J 31: 593–605.

42. ZhangJ, JacksonAF, NaitoT, DoseM, SeavittJ, et al. (2012) Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. Nat Immunol 13: 86–94.

43. HoggPJ, StenfloJ, MosherDF (1992) Thrombospondin is a slow tight-binding inhibitor of plasmin. Biochemistry 31: 265–269.

44. Rodriguez-ManzanequeJC, LaneTF, OrtegaMA, HynesRO, LawlerJ, et al. (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl acad Sci U S A 98: 12485–12490.

45. VassalliJD, SappinoAP, BelinD (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067–1072.

46. VassalliJD, BelinD (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214: 187–191.

47. CarmelietP, MoonsL, LijnenR, BaesM, LemaitreV, et al. (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17: 439–444.

48. BacharachE, ItinA, KeshetE (1992) In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 89: 10686–10690.

49. MazarAP, HenkinJ, GoldfarbRH (1999) The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15–32.

50. BuggeTH, FlickMJ, DaughertyCC, DegenJL (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9: 794–807.

51. PloplisVA, CarmelietP, VazirzadehS, Van VlaenderenI, MoonsL, et al. (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92: 2585–2593.

52. CarmelietP, SchoonjansL, KieckensL, ReamB, DegenJ, et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419–424.

53. BuggeTH, SuhTT, FlickMJ, DaughertyCC, RomerJ, et al. (1995) The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270: 16886–16894.

54. DavisGE, Pintar AllenKA, SalazarR, MaxwellSA (2001) Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 114: 917–930.

55. DavisGE, SaundersWB (2006) Molecular balance of capillary tube formation versus regression in wound repair: role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc 11: 44–56.

56. SaundersWB, BaylessKJ, DavisGE (2005) MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 118: 2325–2340.

57. CarmelietP, StassenJM, SchoonjansL, ReamB, van den OordJJ, et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92: 2756–2760.

58. DoughertyKM, PearsonJM, YangAY, WestrickRJ, BakerMS, et al. (1999) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 96: 686–691.

59. DewerchinM, CollenD, LijnenHR (2001) Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1. Thromb Haemost 86: 640–646.

60. LijnenHR (2001) Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86: 324–333.

61. PatelMK, LymnJS, ClunnGF, HughesAD (1997) Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2107–2114.

62. LawlerJ, SundayM, ThibertV, DuquetteM, GeorgeEL, et al. (1998) Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101: 982–992.

63. ShattilSJ (1995) Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 74: 149–155.

64. Hodivala-DilkeKM, McHughKP, TsakirisDA, RayburnH, CrowleyD, et al. (1999) Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103: 229–238.

65. CoradaM, NyqvistD, OrsenigoF, CapriniA, GiampietroC, et al. (2010) The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell 18: 938–949.

66. MacSweeneyST, PowellJT, GreenhalghRM (1994) Pathogenesis of abdominal aortic aneurysm. Br J Surg 81: 935–941.

67. CarmelietP (2000) Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 105: 1519–1520.

68. KisanukiYY, HammerRE, MiyazakiJ, WilliamsSC, RichardsonJA, et al. (2001) Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 230: 230–242.

69. GriffinCT, CurtisCD, DavisRB, MuthukumarV, MagnusonT (2011) The chromatin-remodeling enzyme BRG1 modulates vascular Wnt signaling at two levels. Proc Natl Acad Sci U S A 108: 2282–2287.

70. GriffinCT, BrennanJ, MagnusonT (2008) The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development. Development 135: 493–500.

71. CarmelietP, LampugnaniMG, MoonsL, BreviarioF, CompernolleV, et al. (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147–157.

72. SchlaegerTM, QinY, FujiwaraY, MagramJ, SatoTN (1995) Vascular endothelial cell lineage-specific promoter in transgenic mice. Development 121: 1089–1098.